| Assessment Status |
Awaiting full HTA submission from Applicant |
| HTA ID |
24005 |
| Drug |
Fezolinetant |
| Brand |
Veoza™ |
| Indication |
Fezolinetant is indicated for the treatment of moderate to severe vasomotor symptoms associated with menopause. |
| Rapid review commissioned |
09/02/2024 |
| Rapid review completed |
12/03/2024 |
| Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of fezolinetant compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE |
08/04/2024 |
| Pre-submission consultation with Applicant |
24/04/2024 |
